Selecta Biosciences

Selecta Biosciences, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. It produces the Synthetic Vaccine Particles (SVP) platform for immune tolerance and immune stimulation. The firm's proprietary pipeline includes SVP-enabled enzyme, oncology and gene therapies. The company was founded by Omid C. Farokhzad, Robert S. Langer Jr., and Ulrich von Andrian in 2007 and is headquartered in Watertown, MA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cartesian Therapeutics, Inc. operates as a clinical-stage biotechnology company. It provides mRNA cell therapies for the treatment of autoimmune diseases. It operates in research and development of cell therapy product candidates. The company is headquartered in Gaithersburg, MD.

WATERTOWN, Mass., April 28, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR® platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that it plans to host a conference call on Thursday, May 5, 2022, at 8:30 a.m. ET to discuss its financial results for the quarter ended March 31, 2022 and provide a business update.

Selecta Biosciences to Host Conference Call and Webcast to Discuss First Quarter 2022 Financial Results and Provide Business Update

WATERTOWN, Mass., April 06, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq: SELB) (“Selecta” or the “Company”), a biotechnology company focused on developing tolerogenic therapies to mitigate unwanted immune responses, today announced that it has agreed to sell 27,428,572 shares of its common stock and accompanying warrants to purchase up to 20,571,429 shares of common stock at a combined offering price of $1.41 per share and accompanying warrant. The warrants to purchase shares of common stock have an exercise price of $1.55 per share, are immediately exercisable and will expire five years from the date of issuance. All of the securities in the offering will be sold by Selecta. The gross proceeds to Selecta from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be approximately $38.7 million. The offering is expected to close on April 11, 2022, subject to the satisfaction of customary closing conditions.

Selecta Biosciences Announces $38.7 Million Underwritten Offering

WATERTOWN, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR® platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Company's Management will participate in a fireside chat and one-on-one investor meetings at the 21st Annual Needham Virtual Healthcare Conference, to be held virtually April 11-14, 2022.

Selecta Biosciences to Participate at the 21st Annual Needham Virtual Healthcare Conference

Selecta Biosciences (SELB) CEO Carsten Brunn on Q4 2021 Results - Earnings Call Transcript

– U.S. Food and Drug Administration (“FDA”) removed clinical hold on SEL-302 for the treatment of patients with methylmalonic acidemia (“MMA”)-

Selecta Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

WATERTOWN, Mass., March 03, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated, precision immune tolerance platform, ImmTOR®, to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that it plans to host a conference call on Thursday, March 10, 2021, at 8:30 a.m. ET to discuss its financial results for the quarter and full-year ended December 31, 2021 and provide a business update.

Selecta Biosciences to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2021 Financial Results and Provide Business Update

WATERTOWN, Mass., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Company's Management will provide a corporate update and participate in one-on-one investor meetings at the SVB Leerink 11th Annual Global Healthcare Conference, to be held virtually February 14-18, 2022.

Selecta Biosciences to Participate at the SVB Leerink 11th Annual Global Healthcare Conference

Ginkgo Bioworks Holdings

WATERTOWN, Mass. and BOSTON, Jan. 10, 2022 /PRNewswire/ --  Selecta Biosciences, Inc. (Nasdaq: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, and Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced a collaboration to develop safer and more effective next-generation gene therapy viral capsids.

Selecta Biosciences and Ginkgo Bioworks Announce New Collaboration to Develop Next-Generation Gene Therapy Capsids

WATERTOWN, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Company's Management will provide a corporate update at the H.C. Wainwright BioConnect Conference, to be held virtually January 10-13, 2022.

Selecta Biosciences to Participate at the 2022 H.C. Wainwright BioConnect Conference

WATERTOWN, Mass., Dec. 29, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Company's Management will participate in a panel and one-on-one investor meetings at the LifeSci Partners 11th Annual Corporate Access Event, to be held virtually January 5-7, 2022.

Selecta Biosciences to Participate at the LifeSci Partners 11th Annual Corporate Access Event

Ensysce Biosciences

Inspira Technologies Oxy BHN Ltd

OPKO Health

4 penny stocks with bullish price targets & buy ratings from analysts. The post 4 Penny Stocks Analysts Say To Buy Now & Targets Up To 117% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

4 Penny Stocks Analysts Say To Buy Now & Targets Up To 117%

Protalix Biotherapeutics

Spruce Biosciences

Tellurian

5 penny stocks with high short interest to add to your watch list in December. The post Best Penny Stocks To Buy?

Best Penny Stocks To Buy? 5 Short Squeeze Stocks To Watch Right Now

Allied Esports Entertainment Inc

Cumberland Pharma

Harbor Custom Development, Inc.

Spark Networks

Outlook Therapeutics Inc

PEDEVCO

Party City Holdco

Vyne Therapeutics

Corporate insiders buy penny stocks & these 10 are getting purchased in December 2021. The post 10 Penny Stocks To Buy In December According To Insiders appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

10 Penny Stocks To Buy In December According To Insiders

STOCKHOLM, Dec. 1, 2021 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO: SOBI) and Selecta Biosciences, Inc. (NASDAQ: SELB), today announced the completion of enrolment for DISSOLVE I, the first of two clinical studies of the phase 3 DISSOLVE development programme of SEL-212 for chronic refractory gout. SEL-212 is a combination of Selecta's ImmTOR™ immune tolerance platform and a therapeutic uricase enzyme (pegadricase).

Sobi and Selecta Biosciences announce completion of enrolment in DISSOLVE Phase 3 study evaluating SEL-212 for chronic refractory gout

-DISSOLVE program on track with 12-month study fully enrolled- -DISSOLVE II on track for full enrollment in early 2022- -Top-line data from Phase 3 DISSOLVE program expected in H2 2022-

Selecta Biosciences and Sobi Announce Completion of Enrollment in DISSOLVE Phase 3 Study Evaluating SEL-212 for Chronic Refractory Gout

The stock price of Selecta Biosciences Inc (NASDAQ: SELB) fell by over 12% pre-market today. This is why it happened.

Selecta Biosciences (SELB) Stock: Why The Price Fell Today

The FDA issues a clinical hold on Selecta's (SELB) phase I/II study evaluating SEL-302 for the treatment of patients with methylmalonic acidemia. Shares down in after-hours trading.

Selecta (SELB) Down on FDA's Clinical Hold on Phase I/II Study

-U.S. FDA has issued a clinical hold on Phase 1/2 Clinical Trial of SEL-302 due to CMC related questions- -U.S. FDA has issued a clinical hold on Phase 1/2 Clinical Trial of SEL-302 due to CMC related questions-

Selecta Biosciences Provides Update on Phase 1/2 Clinical Trial of SEL-302 for the Treatment of Methylmalonic Acidemia

WATERTOWN, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Company's Management will provide a corporate update and participate in one-on-one investor meetings at the Jefferies London Healthcare Conference, to be held virtually November 18-19, 2021.

Selecta Biosciences to Participate in Jefferies Virtual London Healthcare Conference

Selecta Biosciences, Inc.'s (SELB) CEO Carsten Brunn on Q3 2021 Results - Earnings Call Transcript

Selecta Biosciences, Inc. (SELB) delivered earnings and revenue surprises of -128.57% and 82.63%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Selecta Biosciences, Inc. (SELB) Reports Q3 Loss, Tops Revenue Estimates

-Established four strategic collaborations to advance next generation therapeutics and maximize the potential of ImmTOR platform-

Selecta Biosciences Reports Third Quarter 2021 Financial Results and Provides Business Update

Selecta Biosciences Inc (NASDAQ: SELB) announced top-line results from the Phase 1 study evaluating the ImmTOR platform to mitigate the formation of neutralizing antibodies against an adeno-associated viral serotype 8 (AAV8) serotype capsid used in gene therapies.  At day 30, in subjects administered a single 0.3 mg/kg dose of ImmTOR, Selecta observed a median anti-AAV8 neutralizing antibody titer of 1:5, a 250-fold lower level than subjects dosed with AAV8 capsid alone.

Selecta Biosciences Posts Encouraging Data For ImmTOR Platform

- At day 30, of subjects in the 0.3mg/kg ImmTOR cohort, 100% showed NAb titers of ≤ 1:25, and 67% showed NAb titers of ≤ 1:5 -

Selecta Biosciences Announces Top Line Data from the Phase I SEL-399 AAV Empty Capsid Study, Highlighting Potential Benefits of ImmTOR™ in Gene Therapy

WATERTOWN, Mass., Nov. 05, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that it plans to host a conference call on Tuesday, November 9, 2021, at 8:30 a.m. ET to discuss its financial results for the quarter ended September 30, 2021 and provide a business update.

News for Selecta Biosciences Stock (SELB)